Copyright
©The Author(s) 2022.
World J Clin Oncol. May 24, 2022; 13(5): 352-365
Published online May 24, 2022. doi: 10.5306/wjco.v13.i5.352
Published online May 24, 2022. doi: 10.5306/wjco.v13.i5.352
Table 1 Baseline characteristics and age groups (total 225 patients)
| Factor | Group | Alive (%) | P value | < 20 | 20-59 | 60+ | P value | |
| n (%) | 225 | 67 (29.8) | 62 (27.5) | 114 (50.7) | 49 (21.8) | |||
| Median age (IQR) | 27 (19-56) | 15.5 (13-17) | 28.5 (23-44) | 69.0 (65-76) | ||||
| Male (%) | 141 (62.7) | 42 (29.8) | 0.99 | 33 (23.4) | 74 (52.5) | 34 (24.1) | 0.17 | |
| Race (%) | White | 124 (55.1) | 39 (31.5) | 0.66 | 34 (27.4) | 67 (54.3) | 23 (18.6) | 0.07 |
| Black | 27 (12.0) | 8 (29.6) | 6 (22.2) | 16 (59.3) | 5 (18.5) | |||
| API | 22 (9.8) | 4 (18.2) | 3 (13.6) | 9 (40.9) | 10 (45.5) | |||
| Hispanic | 52 (23.1) | 16 (30.8) | 19 (36.5) | 22 (42.3) | 11 (21.2) | |||
| Household income (%) | < $55000 | 55 (24.4) | 20 (36.4) | 0.47 | 16 (29.1) | 32 (58.2) | 7 (12.7) | 0.37 |
| $55000-70000 | 88 (39.1) | 24 (27.8) | 26 (29.6) | 40 (45.5) | 22 (25.0) | |||
| > $70,000 | 82 (36.4) | 23 (28.0) | 20 (24.4) | 42 (51.2) | 20 (24.4) | |||
| Living settings (%) | Population > 1 million | 144 (61.0) | 36 (25.0) | 0.04 | 38 (26.4) | 71 (49.3) | 35 (24.3) | 0.47 |
| Other | 81 (36.0) | 31 (38.3) | 24 (29.6) | 43 (53.1) | 14 (17.3) | |||
| Stages (%) | I | 65 (28.9) | 32 (49.2) | < 0.001 | 13 (20) | 29 (44.6) | 23 (35.4) | 0.02 |
| II | 18 (8.0) | 8 (44.4) | 7 (38.9) | 7 (38.9) | 4 (22.2) | |||
| III | 61 (27.1) | 19 (31.1) | 20 (32.8) | 32 (25.5) | 9 (14.8) | |||
| IV | 61 (27.1) | 2 (3.3) | 20 (32.8) | 34 (55.7) | 7 (11.5) | |||
| Unknown | 20 (8.9) | 6 (30.0) | 2 (10.0) | 12 (60.0) | 6 (30.0) | |||
| Lymph Node status (%) | N0 | 143 (63.6) | 52 (36.4) | 0.009 | 35 (24.5) | 68 (47.6) | 40 (28.0) | 0.004 |
| N1 | 60 (26.7) | 13 (21.7) | 24 (40.0) | 32 (53.3) | 4 (6.7) | |||
| Nx | 22 (9.78) | 2 (9.1) | 3 (13.6) | 14 (63.6) | 5 (22.7) | |||
| Metastasis status (%) | M0 | 154 (68.4) | 64 (41.6) | < 0.001 | 41 (26.6) | 74 (48.05) | 39 (25.3) | 0.16 |
| M1 | 61 (27.1) | 2 (3.3) | 20 (32.8) | 34 (55.7) | 7 (11.5) | |||
| Mx | 10 (4.4) | 1 (10.0) | 1 (10.0) | 6 (60.0) | 3 (30.0) | |||
| Surgery (%) | Wedge/segmental resection | 39 (17.8) | 23 (59.0) | < 0.001 | 15 (38.5) | 17 (43.6) | 7 (18.0) | < 0.001 |
| Lobectomy | 42 (19.2) | 21 (50.0) | 23 (43.4) | 23 (54.8) | 3 (7.1) | |||
| Extended lobectomy | 11 (5.0) | 6 (54.5) | 7 (63.6) | 4 (36.4) | 0 (0) | |||
| Transplant | 19 (8.7) | 7 (36.8) | 6 (31.6) | 13 (68.4) | 0 (0) | |||
| None | 108 (49.3) | 10 (9.3) | 18 (16.7) | 54 (50.0) | 36 (33.3) | |||
- Citation: Sempokuya T, Forlemu A, Azawi M, Silangcruz K, Khoury N, Ma J, Wong LL. Survival characteristics of fibrolamellar hepatocellular carcinoma: A Surveillance, Epidemiology, and End Results database study. World J Clin Oncol 2022; 13(5): 352-365
- URL: https://www.wjgnet.com/2218-4333/full/v13/i5/352.htm
- DOI: https://dx.doi.org/10.5306/wjco.v13.i5.352